Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder

Review

doi: 10.1016/j.pharmthera.2021.107878.

Online ahead of print.

Erica Zamberletti¹, Tiziana Rubino², Daniela Parolaro³

Affiliations

PMID: 33895189
DOI: 10.1016/j.pharmthera.2021.107878

Abstract

Recent years have seen a renewed interest on the possible therapeutic exploitations of specific cannabinoids derived from the Cannabis sativa plant. Thus far, the most studied non-psychotomimetic cannabinoid is cannabidiol (CBD), which has shown promising therapeutic potential for relieving a variety of neurological diseases. However, also its propyl analogue, cannabidivarin (CBDV), has recently gained much attention as a potential therapeutic agent for the management of disabling neurological conditions. This review aims at providing a comprehensive and updated overview of the available animal and human data, which have investigated the possible therapeutic potential of CBDV for the management of epilepsy and autism spectrum disorder.

Keywords: Animal models, Autism spectrum disorder, Cannabidivarin, Epilepsy, Human data

Conflict of interest statement

Declaration of Competing Interest The authors declare that there are no conflicts of interest.

Similar articles

Cannabis sativa: Much more beyond Δ⁹-tetrahydrocannabinol.

Alves P, Amaral C, Teixeira N, Correia-da-Silva G.Pharmacol Res. 2020 Jul;157:104822. doi: 10.1016/j.phrs.2020.104822. Epub 2020 Apr 23.PMID: 32335286 Review.
Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.

Hill TD, Cascio MG, Romano B, Duncan M, Pertwee RG, Williams CM, Whalley BJ, Hill AJ.Br J Pharmacol. 2013 Oct;170(3):679-92. doi: 10.1111/bph.12321.PMID: 23902406 Free PMC article.
Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability.

Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazzarella E, Russo E, Whalley BJ, Di Marzo V, Stephens GJ.ACS Chem Neurosci. 2014 Nov 19;5(11):1131-41. doi: 10.1021/cn5000524. Epub 2014 Jul 29.PMID: 25029033
Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin.

Morano A, Cifelli P, Nencini P, Antonilli L, Fattouch J, Ruffolo G, Roseti C, Aronica E, Limatola C, Di Bonaventura C, Palma E, Giallonardo AT.Epilepsia Open. 2016 Sep 19;1(3-4):145-151. doi: 10.1002/epi4.12015. eCollection 2016 Dec.PMID: 29588939 Free PMC article.
Pharmacology of cannabinoids in the treatment of epilepsy.

Gaston TE, Friedman D.Epilepsy Behav. 2017 May;70(Pt B):313-318. doi: 10.1016/j.yebeh.2016.11.016. Epub 2017 Jan 10.PMID: 28087250 Review.